reducing drug regimens. what is the magic...
TRANSCRIPT
![Page 1: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/1.jpg)
Reducing drug regimens. What is the magic number?
Toxicity and co-morbidities perspective
José I BernardinoHIV Unit. Hospital La Paz
De afbeelding kan niet worden weergegeven.
![Page 2: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/2.jpg)
Financial disclosures
Personal fees from Gilead, Janssen, ViiV healthcare, MSD
![Page 3: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/3.jpg)
Kanters S. Lancet HIV 2016;3:e510-20
![Page 4: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/4.jpg)
Kanters S. Lancet HIV 2016;3:e510-20
Network meta-analysis. Discontinuations due to AE and SAE
![Page 5: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/5.jpg)
REAL life data on DTG Use, OLVG Hospital, Amsterdam.
De Boer. AIDS 2016;30:2832-4
![Page 6: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/6.jpg)
Integrase Inhibitors. EMA SmPCRaltegravir. Special precautions of use. Section 4.4
Genvoya. Adverse effects. Section 4.8
Dolutegravir & Triumeq. Adverse effects. Section 4.8
http://www.ema.europa.eu/ema/index.jsp?curl=pages/home/Home_Page.jsp&mid=
![Page 7: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/7.jpg)
Early D/Cany reason
IRR (95% CI)
Early D/Cdue to AE
IRR(95% CI)
RAL n(%) 71 (12.7) 1 20 (3.6) 1
EVG n(%) 26 (8.1) 0.62 (0.39-0.97) 16 (5) 1.35 (0.70-
2.61)
DTG n(%) 26 (12.3) 0.97 (0.62-1.52) 8 (3.8) 1.66 (0.47-
2.41)
Spanish cohort. RAL 557 EVG 322 DTG 212 German cohort. 1950 INSTI-based in 1704 patients
Peñafiel. JAC 2017. Hoffman. HIV medicine 2017
• Rate of D/C doubled when DTG was combined with ABC/3TC although NS
• Increasing age (4% per year) independent risk factor (aHR 1.04 (1.02-1.07)
• 17 Neuropsychiatric D/C: RAL 7 (35%), EVG 3 (19%), DTG 7 (88%)
D/C because Neuropsychiatric adverse events
• AE leading to D/C was observed in 122 (6.3%) • D/C due to any AE within 24 months:
RAL (3.9%), EVG (12.3%), DTG (9.3%)• Female and > 60 years increased risk for DTG
D/C
![Page 8: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/8.jpg)
Hsu R. CROI Seattle 2017. Poster # 664
Psychiatric disorders. OPERA cohort.
History of psychiatric diagnoses at baseline
DTG (N=2180)EFV (N=1622)RAL (N=917)DRV (N=1759)RPV (N=1758)EVG (N=3303)
![Page 9: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/9.jpg)
Hsu R. CROI Seattle 2017. Poster # 664
Psychiatric disorders. OPERA cohort.
Prevalent and incident psychiatric diagnoses
![Page 10: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/10.jpg)
Smit M. Lancet Infect Dis 2015
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
2010 2012 2014 2016 2018 2020 2022 2024 2026 2028 2030
An individual-based model of an ageing HIV-population following patients on treatment as they age, develop NCDs and start co-administered medications
Clinical Implications of an Ageing HIV Population: ATHENA Cohort
Future Age Distribution of HIV Patientsin the Netherlands
Prop
ortio
n of
peo
ple
Year
>70 yr old
60 - 70 yr old
50 - 60 yr old
40 - 50 yr old
30 - 40 yr old
>30 yr old
In the ATHENA cohort, proportion of patients on ART aged ≥50 years old will increase from 28% to 73% between 2010 and 2030
Burden of NCDs mostly driven by larger increases in cardiovascular disease compared with increases in other comorbidities
In 2030 predictive models suggest: 84% 1 co-morbidity & 28% ≥ 3 co-morbidities
Changes in Relative Number of Patients with Specific NCDs
>30 yr old
CVDDiabetesMalignancy CVD
Diabetes
Malignancy
CVD
Diabetes
Malignancy
2010 2020
2030
![Page 11: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/11.jpg)
Co-morbidities.CoRIS cohort (2004-2014)n = 9569
Alejos B. 21st IAC Durban 2016
![Page 12: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/12.jpg)
Role of ART in co-morbidities
Haematology
Body composition
Cardiovascular disease Hypertension Lipids
Glucose
Pulmonary disease
Liver disease
Renal disease
Bone disease
Neurocognitive impairment Depression
Cancer
Lee H, et al. Biochemistry 2003; 42: 14711-9;Moyle G, et al. Drug Saf 2000; 23: 467-81;Lund, KC et al. AAC 2007, 51: 2531-9.;Carr A. Nat Rev Drug Discover2003; 2: 624-34.;Calmy A. Antivir Ther 2009;14: 165-179.
![Page 13: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/13.jpg)
TOXICITYAGING
COSTSUSTAINABILITY
SIMPLICITYLESS-DRUGS
Reasons for reduced drug regimens
Mitochondrial toxicity (NRTI)
Lipodistrophy (EFV, d4T, ZDV, ddI)
Nephrotoxicity (TDF, ATV, LPV, IDV)
Bone toxicity (TDF, bPI)Cardiovascular toxicity (ABC, bPI)
Metabolic (ABC, bPI)
Neuropsychiatric (EFV, NRTI, INSTI?)
Telomerase inhibition (NRTI)
![Page 14: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/14.jpg)
Study Type of Study N Regimen Results
GARDEL[1] Naive 426 LPV/RTV +3TC Similar efficacy as LPV/RTV + 2NRTIs
PADDLE[2] Naive 20 DTG + 3TC Small study. Encouraging results
NEAT001/ANRS143[3]
Naive 805 DRV/RTV + RAL Similar efficacy as DRV/RTV + TDF/FTC
OLE[4] Switch 250 LPV/RTV + 3TC Similar efficacy as standard ART
SALT[5] Switch 286 ATV/RTV + 3TC Similar efficacy as ATV/RTV + 2 NRTIs
ATLAS-M[6] Switch 266 ATV/RTV + 3TC Similar (improved in post hoc analysis) efficacy vs ATV/RTV + 2NRTIs
DUAL[7] Switch 260 DRV/RTV + 3TC Similar efficacy as DRV/RTV + 2NRTIs
LATTE[8] Switch 243 CAB + RPV Similar efficacy as cont. standard ART
LATTE-2[9] Induction-Maintenance
309 Induct:CAB + ABC/3TCMaint: LA CAB + LA RPV im
Similar efficacy as cont. oral CAB + ABC/3TC;
SWORD[10] Switch 1024 DTG + RPV Similar efficacy as cont standard ART
1.Cahn P et al, EACS 2015, Abstract 9512. Figueroa MI et al EACA 2015. Abstract 10663. Raffi F, et al Lancet 2014;384:1942-19514.Arribas JR et al Lancet Infec Dis 2015; 15:785-7925. Perez-Molina JA et al. Lancet Infect Dis 2015;15:775-784
6. Di Giambenedetto S, et al EACS 2015, Abstract 8677. Fulido F et al. Glasgow 2016 Abstract O 3318. Margolis DA et al. Lancet Infect Dis 2015; 15:1145-11559. Margolis DA et al CROI 2016 Abstract 31LB10. Llibre JM et al CROI 2017 Abstract 2421
Novel TDF-and ABC-Sparing ART Strategies
![Page 15: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/15.jpg)
Renal and Bone safety in ATLAS-M Study
Di Giambenedetto. Glasgow 2016
No differences in Body mass changesNo differences in bone turnover markersSwitch to ATV/RTV +3TC increased cholesterol
![Page 16: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/16.jpg)
Renal and Bone safety in NEAT 001/ANRS143
Creatinine clearance [Cockroft-Gault]Mean (95% CI) change from baseline
Lumbar spine BMDMean % (95% CI) change from baseline
No grade 2-4 creatinine elevation in either arm Although no statistically significant there was a trend for more fractures in the DRV/RTV + TDF/FTC
Raffi F, et al Lancet 2014;384:1942-1951 Bernardino JI, Lancet HIV 2015 11;e464-473
![Page 17: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/17.jpg)
Llibre JM et al. CROI 2017 Abstract 2421
SWORD 1&2 Phase III Study design
![Page 18: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/18.jpg)
Llibre JM et al. CROI 2017 Abstract 2421
Bone turnover markers in SWORD 1&2
![Page 19: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/19.jpg)
GEMINI Studies
![Page 20: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/20.jpg)
With newer and safer drugs as TAF,is there still room for less drug
regimens?
![Page 21: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/21.jpg)
• At Week 24, median (Q1, Q3) change from baseline in eGFRCG was -0.4 (-4.8, 4.5) mL/min, and in eGFRCKD-EPI, cystatin C was 3.8 (-4.8, 11.2) mL/min/1.73 m2
• There was no significant change in eGFRCG or eGFRCKD-EPI, cystatin C to Week 48
0 4 8 12 16 24 36 48-10
-5
0
5
10
15
0.6-1.4
1.81.1
Primary Endpoint
-10
-5
0
5
10
15
Weeks
Primary EndpointChange in eGFR (CKD-EPI, Cystatin C)
Change in eGFR (Cockcroft-Gault)M
edia
n (Q
1,Q
3) e
GFR
Cha
nge
From
Bas
elin
e (m
L/m
in)
Med
ian
(Q1,
Q3)
eG
FRC
hang
eFr
om B
asel
ine
(mL/
min
/1.7
3 m
2 ))
<50 mL/minBaseline eGFRCG
0 4 8 12 16 24 36 48
Change in eGFR From Baseline to Week 48. Study GS 112
Pozniac A . CROI 2015 Poster 795
![Page 22: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/22.jpg)
Median changes in eGFRCKD_EPI by Age. GS112 Sub analysis
Martorell C. HIV and Aging. Washington DC Poster 36
![Page 23: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/23.jpg)
Tenofovir alafenamida. Study GS104 &111. 144 weeks
At Week 144, median change from baseline in eGFR CG was significantly lower with E/C/F/TAF vs E/C/F/TDF (1.6 vs 7.7 ml/min) p < 0.001
Arribas JR . CROI 2017 Poster 453
![Page 24: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/24.jpg)
Goldstein D. HIV and Aging. Washington DC Poster 32
Mean change in BMD (%) by < 50 or ≥ 50 years. GS 109
![Page 25: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/25.jpg)
Substudy GS109 &112
Brown T. CROI 2017 Poster 683
214 (19%) had a significant low BMD at baseline (T scores ≤ -2)
27% had > 5% increase in BMD at spine and 16% at total hipReversion from osteoporosis observed in 23%
Changes in BMD (%) through w96 Changes in T-score through w96
![Page 26: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/26.jpg)
![Page 27: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/27.jpg)
• TTAGGG• Shorten each mitotic
cycle• Senescence - apoptosis
TELOMERASE• Celular reverse
transcriptase- hTERT: Catalytic unit
(Reverse transcriptase)
Telomere & Telomerase
![Page 28: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/28.jpg)
![Page 29: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/29.jpg)
Stella-Ascariz N et al, JAIDS 2017
![Page 30: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/30.jpg)
Montejano R et al, JAIDS 2017
![Page 31: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/31.jpg)
Montejano R et al, JAIDS 2017
![Page 32: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/32.jpg)
![Page 33: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/33.jpg)
EPIGENETIC CLOCK METHOD
![Page 34: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/34.jpg)
DNAm Age and telomere length on the same samples
Framingham Heart study. Brian Chen
![Page 35: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/35.jpg)
![Page 36: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/36.jpg)
HIV+ patients had a biological age advancement of 4.9 years on average (CI 95% 3.4-7.1years)Decreased HLA methylation is predictive of lower CD4+/CD8+ ratioAge advancement occurs early in the course of disease as a consequence of acute infection or reaction to drug treatment
![Page 37: Reducing drug regimens. What is the magic number?regist2.virology-education.com/2017/2ndSpanHCF/10_Bernardino.pdf · REAL life data on DTG Use, OLVG Hospital, Amsterdam. De Boer](https://reader031.vdocuments.mx/reader031/viewer/2022011921/603b182cb81ba84659590f82/html5/thumbnails/37.jpg)
Points for discussion• Are CNS effects related to integrase inhibitors really an issue?
• Overall data regarding long-term toxicity are lacking in less drug regimens
• With the safety profile of TAF, is there still room for less drugs regimens?
• Should all patients on TDF-based regimens be proactively switched to TAF-based regimens?
• The role of ART in the Aging process deserve further studies (Telomere length, DNA methylation changes…)